Hjem
Nasjonal kompetansetjeneste og forskningsgruppe for multippel sklerose

Varselmelding

There has not been added a translated version of this content. You can either try searching or go to the "area" home page to see if you can find the information there

Hovedinnhold

Backgound and vision

Clinical research aims to explore the progression of the disease and to evaluate new potential treatment options for patients with MS.

Ongoing projects

Prospective study on antibiotics use and tonsilectomy as risk factors for MS 

 

Time frame: 2014 - 2021

Please contact: Trond Riise
E-mail: Trond.riise@uib.no

Early treatment and monitoring of patients with MS

 

Time frame: 2020 - 2021

Cooperation with: 

Please contact: Øivind Fredvik Torkildsen
E-mail: oivind.fredvik.grytten.torkildsen@helse-bergen.no

Nordic observational study on the efficacy of Lemtrada© (Alemtuzumab) on fatigue and quality of life

 

Time frame: 2016 - 2021

Cooperation with: Helse Vest. Helse Sør-Øst, Helse Nord, Helse Midt-Norge
International cooperation with: 

Please contact: Øivind Fredvik Torkildsen
E-mail: oivind.fredvik.grytten.torkildsen@helse-bergen.no

The efficacy and safety of hematopoietic stem cell treatment in Multiple Sclerosis-The first Norwegian results

Autologous stem cell treatment is a promising treatment option in MS, but so far relatively few patients have been treated in Norway.The object of this study is to evaluate and describe the outcome of HSCT treatment for all Norwegian patients receiving HSCT from Jan. 2015 to Jan. 2018. The method is retrospective evaluation of medical records. The study is approved by the Regional Ethical Committee and written consent has been collected from all patients. 

Time frame for the project is until 2020.

Please contact: Silje Stokke Kvistad (PhD-candidate)
E-mail: sgns@helse-bergen.no
Phone: +47 55 97 58 47

Norwegian Multiple Sclerosis Competence Centre
Dept. of Neurology
Haukeland University Hospital
5021 Bergen

Cognitive function in the early stages of MS

Objective: Validation of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) test battery and evaluation of the extent of cognitive dysfunction in a Norwegian population of MS patients in the early stages of the disease.

Methods: MS-patients with onset of symptoms no more than 3 years prior to diagnosis 2014-2017 are tested with BICAMS at baseline and again after 12 and 24 months. 3T MRI of brain and spinal cord is taken around the same time for evaluation of radiological markers for cognitive dysfunction.

Timeframe: 2017-2021

Please contact: Ellen Skorve (Phd-candidate) 
E-mail: ellen-skorve@helse-bergen.no

Norwegian Multiple Sclerosis Competence Centre
Dept. of Neurology
Haukeland University Hospital
5021 Bergen